Wedbush Initiates Coverage on Bicara Therapeutics (NASDAQ:BCAX)

Wedbush initiated coverage on shares of Bicara Therapeutics (NASDAQ:BCAX) in a report published on Thursday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $31.00 price target on the stock.

BCAX has been the subject of a number of other research reports. RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a research note on Tuesday, November 5th. They set a “buy” rating and a $48.00 target price for the company. Finally, HC Wainwright raised their price target on Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $41.20.

Bicara Therapeutics Stock Performance

Bicara Therapeutics stock opened at $12.60 on Thursday. The stock’s fifty day moving average is $16.00. Bicara Therapeutics has a twelve month low of $11.10 and a twelve month high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($1.14). Analysts predict that Bicara Therapeutics will post -2.59 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Spire Wealth Management acquired a new stake in shares of Bicara Therapeutics during the fourth quarter worth $31,000. SG Americas Securities LLC purchased a new stake in shares of Bicara Therapeutics in the fourth quarter valued at about $147,000. Cinctive Capital Management LP acquired a new position in shares of Bicara Therapeutics during the third quarter worth about $229,000. Barclays PLC acquired a new position in shares of Bicara Therapeutics during the third quarter worth about $255,000. Finally, Jane Street Group LLC purchased a new position in Bicara Therapeutics during the third quarter worth about $309,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.